Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

FCE-28068

Known as: FCE28068 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate
PurposeIntravenously (i.v.) administered nanomedicines have the potential for tumour targeting due to the enhanced permeability… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled… Expand
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
Is this relevant?
Review
2009
Review
2009
Clinical experience with anthracycline antibiotics-HPMA copolymer-human immunoglobulin conjugates.
  • B. Říhová
  • Advanced drug delivery reviews
  • 2009
    • Corpus ID: 20423172
This paper reviews an early clinical experience with anthracycline (epirubicin; Epi or doxorubicin; Dox) containing an N-(2… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells.
Recently we have described an HPMA copolymer conjugate carrying both the aromatase inhibitor aminoglutethimide (AGM) and… Expand
Is this relevant?
2007
2007
Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates.
Our past research developed two N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin (Dox) conjugates that became the… Expand
Is this relevant?
Review
2005
Review
2005
Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer.
The last decade has seen successful clinical application of polymer-protein conjugates (e.g. Oncaspar, Neulasta) and promising… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic.
There are now at least seven polymer-drug conjugates that have entered phase I/II clinical trial as anticancer agents. These… Expand
  • figure 1
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE